It has been shown that the sympathetic nervous system is activated in pulmonary arterial hypertension (PAH). Norepinephrine (NE) levels are increased by chemoreflex-dependent sympathetic overactivation and involved in pulmonary vascular remodeling. However, the underlying mechanisms of the remodeling induced by NE are poorly understood. In this study, we found that, in vivo, the expression of tyrosine hydroxylase and the concentration of plasma NE were increased in PAH rats compared with normal rats. Increases in ventricular hypertrophy and medial width of the pulmonary arteries were reversed by prazosin, α-adrenoceptor (α-AR) antagonists, in PAH rats. Elevated expression of α-AR was detected in PAH rats. In addition, prazosin reduced the increasing expression of PCNA, CyclinA and CyclinE induced by hypoxia. In vitro, MTT assay, flow cytometry, Western blotting and immunofluorescence were performed to investigate the effects of NE on proliferation of pulmonary artery smooth muscle cells (PASMCs). We revealed that NE promoted PASMCs viability, increased the expression of PCNA, CyclinA and CyclinE, made more cells from G/G phase to G/M+S phase and enhanced the microtubule formation. Above NE-induced changes could be suppressed by BMY 7378, an inhibitor of α-AR. Furthermore, ERK-1/2 pathway was activated by NE. U0126, a specific inhibitor for ERK-1/2, attenuated the NE-induced proliferation of PASMCs under normoxia and hypoxia. Taken together, our results suggest that NE which stimulates α-AR promotes proliferation of PASMCs and the effect is, at least in part, mediated via the ERK-1/2 pathway.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2017.05.001DOI Listing

Publication Analysis

Top Keywords

pah rats
12
promotes proliferation
8
proliferation pulmonary
8
pulmonary artery
8
artery smooth
8
smooth muscle
8
muscle cells
8
expression pcna
8
pcna cyclina
8
cyclina cycline
8

Similar Publications

Pulmonary arterial hypertension (PAH) is a serious medical condition that causes a failure in the right heart. Two-pore channel 2 (TPC2) is upregulated in PAH, but its roles in PAH remain largely unknown. Our investigation aims at the mechanisms by which TPC2 regulates PAH development.

View Article and Find Full Text PDF
Article Synopsis
  • Exercise training is increasingly recognized as a valuable addition to medical treatment for pulmonary arterial hypertension (PAH), but the metabolic changes it induces are not well understood.
  • The study involved male Wistar rats, which were divided into four groups, with some undergoing treadmill exercise for five weeks to analyze metabolic effects.
  • Results indicated significant alterations in lipid and amino acid metabolism due to PAH, but exercise helped restore normal levels of arginine and homocysteine, potentially improving PAH outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • A newly optimized compound showed potent inhibition of PDE5A with an impressive selectivity over other PDE enzymes, indicating strong potential as a treatment option.
  • In animal studies, the compound outperformed sildenafil in reducing mean pulmonary artery pressure and right ventricle hypertrophy, suggesting it could be a promising new therapy for PAH.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigated whether combined moderate-intensity exercise could slow down harmful changes in the lungs and right heart in rats with pulmonary arterial hypertension (PAH) induced by monocrotaline (MCT).
  • Rats underwent a 3-week exercise program including aerobic and resistance training, which improved their physical endurance and prevented negative changes in pulmonary artery resistance and right ventricular function.
  • The exercise also helped maintain heart cell function, reduced structural damage to the right ventricle and lungs, and lowered oxidative stress levels associated with PAH.
View Article and Find Full Text PDF

Serum proteome profiling reveals HGFA as a candidate biomarker for pulmonary arterial hypertension.

Respir Res

November 2024

National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.

Background: Identification and validation of potential biomarkers could facilitate the identification of pulmonary arterial hypertension (PAH) and thus aid to study their roles in the disease process.

Methods: We used the isobaric tag for relative and absolute quantitation approaches to compare the protein profiles between the serum of PAH patients and the controls. Bioinformatics analyses and enzyme-linked immunosorbent assay (ELISA) identification of PAH patients and the controls were performed to identify the potential biomarkers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!